Imagine discovering a hidden enemy lurking within your genes, one that could increase your cancer risk but has remained undetected—until now. A groundbreaking study has unveiled a previously unknown class of BRCA1 mutations and a potential way to target them, offering new hope for personalized cancer treatment. But here's where it gets controversial: could a protein meant to protect our cells actually be shielding harmful mutations, delaying cancer onset but complicating treatment? Let’s dive in.
Researchers at The University of Texas MD Anderson Cancer Center have uncovered a surprising role for heat shock protein 90 (HSP90) in cancer predisposition and treatment resistance. Their findings, published in Molecular Cell, reveal that HSP90 acts as a buffer for certain BRCA1 mutations, masking their harmful effects and postponing the development of breast cancer. This buffering mechanism, while protective in the short term, creates a vulnerability in cancer cells that could be exploited therapeutically. By targeting HSP90, scientists believe they can overcome treatment resistance, particularly in patients with specific BRCA1 mutations.
Led by Georgios Karras, Ph.D., the study identifies predictive features of HSP90 buffering in patients with these mutations, paving the way for personalized diagnosis, prognosis, and combination therapies. As Karras explains, ‘Mutations are not all the same. Understanding the mechanisms that distinguish them can improve our ability to predict clinical outcomes and target mutations more effectively.’
But here’s the part most people miss: HSP90, a protein known for protecting cells from stress, also acts as a silent guardian of genetic mutations. It helps proteins fold correctly and masks mutations that would otherwise cause dysfunction. However, its role in human health has been unclear—until now. This discovery raises a thought-provoking question: Could HSP90’s buffering effect be both a blessing and a curse, delaying cancer onset but complicating treatment?
The BRCA1 gene is a critical tumor suppressor, protecting against breast and ovarian cancers. Mutations that inactivate it can disrupt genome maintenance pathways, increasing cancer risk. The researchers found that HSP90 buffers certain BRCA1 mutations, allowing them to persist in populations and delaying cancer onset in carriers. Controversially, this buffering also makes cancer cells resistant to PARP inhibitor treatment, a common therapy for BRCA1-related cancers. However, the study shows that adding a low-dose HSP90 inhibitor can overcome this resistance, offering a new combination treatment strategy.
Interestingly, HSP90’s ability to buffer mutations is fragile and can be disrupted by environmental changes, such as a fever. This vulnerability opens the door for targeted therapies. Further analysis identified specific predictive features of HSP90 buffering, enabling better patient classification and treatment planning.
What does this mean for patients? Many cancer patients carry HSP90-buffered BRCA1 mutations, suggesting they could benefit from low-dose HSP90 inhibition alongside PARP inhibitors. Highly selective HSP90 inhibitors are already in clinical trials and show promise. However, more research is needed to confirm their effectiveness.
This article is republished from MD Anderson Cancer Center. For further details, contact the cited source. Our press release policy is available here.
Thought-provoking question for you: If HSP90’s buffering effect delays cancer onset but complicates treatment, should we prioritize early detection of these mutations or focus on developing therapies that target HSP90? Share your thoughts in the comments below!
